Nasus Pharma Ltd. (NSRX) — Working Capital to Net Assets Ratio
Nasus Pharma Ltd. (NSRX) has a Working Capital to Net Assets ratio of 97.3% as of December 2025. Working capital of $2.69 Million (current assets of $4.86 Million minus current liabilities of $2.16 Million) is measured against net assets of $2.77 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Nasus Pharma Ltd. (NSRX) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Nasus Pharma Ltd. Working Capital to Net Assets (2022–2025)
This chart shows how Nasus Pharma Ltd.'s Working Capital to Net Assets ratio has evolved across 4 annual periods from 2022 to 2025. As of December 2025, the ratio stands at 97.3%, reflecting working capital of $2.69 Million against net assets of $2.77 Million USD. Check how tangible is Nasus Pharma Ltd.'s equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Nasus Pharma Ltd. (2022–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Nasus Pharma Ltd. from 2022 to 2025, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market value of Nasus Pharma Ltd..
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 97.3% | $2.69 Million | $2.77 Million | $4.86 Million | $2.16 Million | ▼ -10.8 pp |
| 2024 | 108.1% | $-3.47 Million | $-3.21 Million | $457.00K | $3.93 Million | ▲ +8.1 pp |
| 2023 | 100.0% | $-3.80 Million | $-3.80 Million | $444.00K | $4.24 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $-2.79 Million | $-2.79 Million | $417.00K | $3.20 Million | — |